ThromboGenics to present a preclinical overview of its two most advanced diabetic eye disease clinical candidates, THR-317 and THR-149, at EASDec 2018

 

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company developing novel medicines for diabetic eye disease, announces that its CSO Jean Feyen, PhD, and Senior Scientist Tine Van Bergen, PhD, will present at the European Association for the Study of Diabetes Eye Complications Study Group (EASDec) Annual Meeting 2018, which takes place from the 24-26 May in Belfast, Northern Ireland.

The presentations will provide an overview of the extensive preclinical evidence supporting the potential benefits of its two promising pipeline candidates THR-317, a humanized monoclonal antibody neutralizing placental growth factor (PIGF), and THR-149, a plasma kallikrein inhibitor, in the treatment of diabetic macula edema (DME).

Dr Jean Feyen, will present on THR-317, currently in a Phase 2 study in combination with anti-VEGF ranibizumab for the treatment of DME. In pre-clinical models, anti-PlGF has shown to reduce DME disease hallmarks; it has demonstrated anti-angiogenic properties as well as potential additional benefits compared to VEGF inhibitors (current standard of care), including anti-inflammation.

Dr Tine Van Bergen will present on THR-149, which is on track to enter Phase 1 clinical studies for the treatment of DME. Preclinical studies have demonstrated the potency and efficacy of bicyclic peptide inhibitors of PKal, such as THR-149, via a VEGF-independent pathway.

Details of the presentations are as follows:

Presenter: Jean Feyen
Title: Neutralization of placental growth factor reduces retinal inflammation in diabetic animal models
Date: Saturday 26 May 2018
Time: 12.14
Location: Riddel Hall, Centre for Experimental Medicine, Queen's University Belfast

Presenter: Tine Van Bergen
Title: Targeting plasma kallikrein with a novel bicyclic peptide inhibitor reduces retinal leakage in a diabetic rat model
Date: Saturday 26 May 2018
Time: 12.27
Location: Riddel Hall, Centre for Experimental Medicine, Queen's University Belfast

EASDec aims to promote the advancement of knowledge of all aspects of diabetic retinopathy, including epidemiology, pathology, pathophysiology, investigation and treatment through active collaboration between ophthalmologists and diabetologists.

Note

ThromboGenics is a biopharmaceutical company focused on developing innovative treatments for diabetic eye disease. The company's pipeline of disease modifying drug candidates is targeting the key segments of the diabetic eye disease market.
ThromboGenics' clinical pipeline consists of THR-317, a PlGF inhibitor, for the treatment of diabetic macular edema (DME), which is in an ongoing Phase 2 clinical study in combination Lucentis®, and THR-149, a plasma kallikrein inhibitor which is targeted to enter the clinic in Q2 2018. Another candidate, THR-687 (an integrin antagonist) is in late-stage preclinical development for the treatment of diabetic retinopathy and DME. THR-687 is expected to enter the clinic around mid-2018. Further new drug candidates are currently being assessed and developed for the treatment of diabetic eye disease.


ThromboGenics owns the global rights to JETREA® (ocriplasmin), the only pharmacological vitreolysis drug approved for the treatment of symptomatic vitreomacular adhesion (in the US) and vitreomacular traction (outside the US).
ThromboGenics is headquartered in Leuven, Belgium, and is listed on the NYSE Euronext Brussels exchange under the symbol THR. More information is available at www.thrombogenics.com

 

 

Interested in a regular update of the Life Sciences and biotech sector in Flanders?